ASCO President Presses Medicare to Cover Costs of Cancer Clinical Trial Participants

Publication
Article
OncologyONCOLOGY Vol 13 No 5
Volume 13
Issue 5

Allen Lichter, MD, president of the American Society of Clinical Oncology (ASCO), stated at a meeting sponsored by the

Allen Lichter, MD, president of the American Society of Clinical Oncology (ASCO), stated at a meeting sponsored by the Institute of Medicine (IOM) that Medicare should pay routine patient costs for people who participate in qualified clinical trials of cancer treatments. The issue of reimbursement for clinical trial participants has been controversial for years, of course. Sens. Connie Mack (R-FL) and Jay Rockefeller (D-W. Va.) were scheduled to reintroduce their clinical trials bill in April. It creates a small “demonstration program”.

The IOM, which is part of the National Academy of Sciences, will make a report on clinical trials reimbursement to the Health Care Financing Administration by September 30. “It is ASCO’s view that Medicare beneficiaries who have paid premiums and taxes should be entitled to expect coverage of their hospital and physician costs and routine diagnostic tests that would be administered regardless of whether the patient was enrolled in a trial,” Lichter said at the IOM meeting.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content